Key Facts

• A new targeted drug doubled survival time for pancreatic cancer patients compared to chemotherapy.
• Pancreatic cancer is expected to be the second leading cause of cancer death in the U.S. by 2030.
• The new drug is undergoing FDA approval but is already available in an expanded access program.
• Studies suggest that GLP-1 agonists might lower the risk of obesity-related cancers and reduce cancer coming back.
• It's still unclear if the benefits of GLP-1 drugs are due to weight loss or other biological effects.
• City of Hope introduced a new plan to help cancer patients after their active treatment ends, focusing on quality of life.
• The cancer care community is shifting focus from only extending life to helping patients live well after cancer.
• Health systems are encouraged to assist patients with the ongoing physical, emotional, and financial challenges post-cancer.